T cells including CD8+ and CD4+ T cells play significant roles in mediating durable anti-tumor immunity (18–21), making them feasible in predicting the responses to ICI immunotherapy in clinic (8, 11, 22–24). This evidence concerns the gene CD8A and neoplasm.